Hostname: page-component-89b8bd64d-nlwjb Total loading time: 0 Render date: 2026-05-07T15:45:17.084Z Has data issue: false hasContentIssue false
  • English
  • Français

Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): blocking 5HT3 receptors enhances release of serotonin, norepinephrine, and acetylcholine

Published online by Cambridge University Press:  30 June 2015

Stephen M. Stahl
Rights & Permissions [Opens in a new window]

Abstract

Vortioxetine is an antidepressant with multiple pharmacologic modes of action at targets where serotonin neurons connect with other neurons. 5HT3 receptor antagonism is one of these actions, and this leads to increased release of norepinephrine (NE), acetylcholine (ACh), and serotonin (5HT) within various brain circuits.

Information

Type
Brainstorms
Information
CNS Spectrums , Volume 20 , Issue 5 , October 2015 , pp. 455 - 459
Copyright
© Cambridge University Press 2015 

Take-Home Points

  • 1. Vortioxetine is an antagonist at serotonin (5HT) 5HT3 receptors.

  • 2. Vortioxetine also targets the serotonin transporter (SERT), 5HT1A, 5HT1B, 5HT1D, and 5HT7 receptors.

  • 3. 5HT3 antagonism enhances not only the release of 5HT, but also of norepinephrine (NE) and acetylcholine (ACh), which may be linked to its antidepressant and procognitive properties.

Vortioxetine is a “multimodal” agent that simultaneously acts at 6 pharmacologic targets with 3 modes of action (Figure 1)Reference Mørk, Pehrson and Brennum1–Reference Sanchez, Asin and Artigas4:

  1. 1. Inhibition of the serotonin (5HT) transporter or SERT

  2. 2. Actions at several G-protein linked receptors (agonist actions at 5HT1A receptors, partial agonist actions at 5HT1B receptors, antagonist actions at 5HT1D and 5HT7 receptors)

  3. 3. Inhibition of a ligand-gated ion channel (the 5HT3 receptor)

Figure 1

Icon of vortioxetine showings its 6 pharmacologic mechanisms. Highlighted here is 5HT3 antagonism, linked to enhanced release of serotonin (5HT), NE, and ACh.

We have previously described the mechanisms whereby vortioxetine’s actions at 5HT receptors work together to enhance the release of 5HTReference Stahl5 and glutamateReference Stahl6 and to inhibit the release of GABA (gamma amino butyric acid).Reference Stahl6 Here we discuss how antagonism of 5HT3 receptors by vortioxetine (Figure 1) is one of the hypothetical mechanisms that also leads to enhanced release of 5HT as well as to enhanced release of NE and ACh.Reference Pehrson, Cremers and Bétry3, Reference Sanchez, Asin and Artigas4, Reference Stahl7, Reference Mørk, Montezinho and Miller8 An explanation of vortioxetine’s hypothetical actions at additional 5HT receptors that also contribute to the enhanced release of ease of NE and ACh, as well as to the release of DA and histamine HA, has been discussed elsewhere.Reference Pehrson, Cremers and Bétry3, Reference Sanchez, Asin and Artigas4, Reference Stahl7, Reference Mørk, Montezinho and Miller8

Serotonin and Glutamate Regulate Each Other

It is well known that 5HT regulates its own release via feedback mediated by autoreceptors that are located on the 5HT neurons themselves.Reference Stahl5, Reference Stahl9, Reference Fink and Gothert10 However, 5HT can also regulate its own release via postsynaptic 5HT3 receptors located within a 3-neuron feedback loop (Figure 2A).Reference Fink and Gothert10–Reference Ashby, Minabe, Edwards and Wang15 The first neuron in this feedback loop is serotonergic, and provides input to prefrontal cortex and hippocampus. There, 5HT stimulates excitatory 5HT3 receptors on a GABAergic interneuron (Figure 2A). This second neuron in the feedback loop is a type of GABAergic interneuron that does not stain positively for the calcium binding protein parvalbumin and is regular spiking, late spiking, or bursting in its firing pattern.Reference Stahl6, Reference Fink and Gothert10–Reference Gottlieb and Keller28 The GABA that is released from this second neuron in turn inhibits the third neuron in the feedback loop, namely, a pyramidal neuron in the prefrontal cortex or hippocampus (Figure 2A). This pyramidal neuron finally projects back to the midbrain raphe where it can release glutamate and stimulate 5HT release (Figure 2A). Thus, 5HT regulates downstream glutamate release, which in turn regulates 5HT release (Figure 2A).

Figure 2A

Serotonin and glutamate regulate each other: role of 5HT3 receptors. Shown here is a 3-neuron feedback circuit, beginning with the 5HT neuron, terminating upon a 5HT3 receptor localized upon a second neuron: a GABAergic interneuron that does not stain positively for the calcium binding protein parvalbumin and has a firing pattern that is regular spiking, late spiking or bursting. GABA released from this second neuron in turn inhibits the third neuron in this feedback circuit: cortical pyramidal neurons that release glutamate at nerve terminals that project back to the midbrain raphe and that stimulate 5HT release.

Although SSRIs increase 5HT levels by SERT inhibition, activation of 5HT3 receptors by 5HT in this feedback loop leads to inhibition of cortical pyramidal neurons due to activation of GABAergic inhibition, and thus no amplification of 5HT release by downstream glutamate (Figure 2B).Reference Fink and Gothert10–Reference Ashby, Minabe, Edwards and Wang15 Contrast this with vortioxetine, which not only enhances 5HT via SERT inhibition, but also blocks 5HT3 receptors (Figure 2C). 5HT3 receptor antagonism removes GABAergic inhibition and thus disinhibits pyramidal neurons, further enhancing 5HT release by glutamatergic stimulation of serotonergic neurons in the midbrain raphe (Figure 2C).Reference Pehrson, Cremers and Bétry3, Reference Sanchez, Asin and Artigas4, Reference Dale, Zhang and Leiser16, Reference Bétry, Pehrson and Etievant17

Figure 2B

When 5HT levels increase after administration of an SSRI, the activation of 5HT3 receptors by 5HT leads to stimulation of GABA release; this in turn inhibits cortical pyramidal neurons, and thus there is no amplification of 5HT release by downstream glutamate.

Figure 2C

In contrast to the actions of SSRIs shown in Figure 2B, shown here are the actions of vortioxetine, which not only enhance 5HT via SERT inhibition, but also block 5HT3 receptors. The blockade of 5HT3 receptors removes GABA inhibition and thus disinhibits pyramidal neurons. This in turn enhances downstream release of 5HT due to glutamatergic stimulation of serotonergic neurons in the midbrain raphe.

Serotonergic Regulation of Norepinephrine (NE) and Acetylcholine (ACh) Release

5HT regulates the downstream release of many neurotransmitters, not only 5HT itself, but also NE, ACh, DA, and HA.Reference Pehrson, Cremers and Bétry3, Reference Sanchez, Asin and Artigas4, Reference Stahl9, Reference Fink and Gothert10, Reference Artigas18, Reference Pehrson and Sanchez24 Stimulation of postsynaptic 5HT1A receptors increases cortical and hippocampal release of AChReference Izumi, Washizuka, Miura, Hiraga and Ikeda29, Reference Consolo, Ramponi, Ladinsky and Baldi30 and NE.Reference Suzuki, Matsuda, Asano, Somboonthum, Takuma and Baba31, Reference Suwabe, Kubota, Niwa, Kobayashi and Kanba32 Although the microanatomy is still being worked out, blockade of postsynaptic serotonergic heteroreceptors on presynaptic nerve terminals could theoretically be another mechanism whereby ACh, NE, DA, and HA release is enhanced.Reference Mørk, Montezinho and Miller8, Reference Fink and Gothert10 These various mechanisms are discussed elsewhere.Reference Pehrson, Cremers and Bétry3, Reference Sanchez, Asin and Artigas4, Reference Stahl7–Reference Fink and Gothert10 Here we discuss and illustrate how 5HT3 receptors regulate both NE and ACh release. Specifically, 5HT stimulation of 5HT3 receptors causes inhibitory output from GABAergic interneurons, and this inhibits the release of NE and ACh from presynaptic nerve terminals (Figure 3A).Reference Matsumoto, Yoshioka, Togashi, Tochihara, Ikeda and Saito19, Reference Yan20 Thus, when SSRIs elevate 5HT levels, this causes GABA to be released, which in turn inhibits both NE and ACh release (Figure 3B).Reference Matsumoto, Yoshioka, Togashi, Tochihara, Ikeda and Saito19, Reference Yan20 By contrast, vortioxetine blocks the 5HT3 receptor so that GABA is not released by 5HT, and therefore both NE and ACh are disinhibited—ie, their levels are enhanced (Figure 3C).Reference Bang-Andersen, Ruhland and Jorgensen2, Reference Mørk, Montezinho and Miller8

Figure 3A

Serotonin (5HT) 3 receptor mediated regulation of ACh and NE release. 5HT stimulation of 5HT3 receptors causes inhibitory output from GABAergic interneurons, and this inhibits the release of NE and ACh from presynaptic nerve terminals.

Figure 3B

SSRIs inhibit the release of ACh and NE via 5HT3 receptors. When SSRIs increase 5HT levels by SERT inhibition, GABA is released, which in turn inhibits both NE and ACh release.

Figure 3C

Vortioxetine enhances the release of ACh and NE by blocking 5HT3 receptors. By contrast with SSRI actions shown in Figure 3B, vortioxetine blocks the 5HT3 receptor so that GABA is not released by 5HT, and therefore both NE and ACh are disinhibited—ie, their levels are enhanced.

Potential Clinical Significance of 5HT3 Antagonism

Enhanced release of 5HT by combining 5HT3 antagonism with SERT inhibition likely contributes to the antidepressant actions of vortioxetine.Reference Mørk, Pehrson and Brennum1–Reference Sanchez, Asin and Artigas4, Reference Mørk, Montezinho and Miller8, Reference Pehrson and Sanchez24 Enhanced 5HT release by combining SERT inhibition with several of vortioxetine’s other actions at 5HT receptors—namely 5HT1A agonism, 5HT1B partial agonism, 5HT1D antagonism, and 5HT7 antagonism—was discussed in a previous Brainstorms article.Reference Stahl5 Enhanced release of NE and ACh levels is also likely an important feature of vortioxetine’s clinical activity. That is, NE and ACh levels are increased with selective 5HT3 antagonists that also exhibit procognitive activity in animal models.Reference Brambilla, Ghiorzi, Pitsikas and Borsini33–Reference Arnsten, Line, Van Dyck and Stanhope37 Thus, vortioxetine’s procognitive actions in both animal modelsReference Pehrson and Sanchez24, Reference du Jardin, Jensen, Sanchez and Pehrson38–Reference Wallace, Pehrson, Sánchez and Morilak41 and in patients with major depressive disorderReference Katona, Hansen and Olsen42–Reference Mahableshwarkar, Zajecka, Jacobson, Chen and Keefe44 may be mediated in part by its 5HT3 antagonist properties and the enhanced release of both NE and ACh that accompany 5HT3 receptor antagonism. Adding 5HT3 antagonism to SSRI actions could potentially enhance not only the antidepressant actions of SSRI activity but also add procognitive actions to antidepressant actions via increased release of 5HT, ACh, and NE. This possibility fits with the notion that neurotransmitters may theoretically “tune” the malfunctioning brain circuits that cause psychiatric symptoms.Reference Stahl6, Reference Dale, Zhang and Leiser16, Reference Insel, Cuthbert and Garvey45, Reference Stahl46 The release of 5HT, NE, and ACh by vortioxetine could theoretically improve the efficiency of information processing in maladaptive brain circuits by facilitating long-term potentiation, synaptic plasticity, and enhanced pyramidal neuron activity leading to improvement not only of mood but also of cognitive symptoms in major depressive disorder.

References

1.Mørk, A, Pehrson, A, Brennum, LT, et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther. 2012; 340(3): 666–675.CrossRefGoogle ScholarPubMed
2.Bang-Andersen, B, Ruhland, T, Jorgensen, M, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011; 54(9): 3206–3221.CrossRefGoogle ScholarPubMed
3.Pehrson, AL, Cremers, T, Bétry, C, et al. Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters—a rat microdialysis and electrophysiology study. Eur Neuropsychopharmacol. 2013; 23(2): 133–145.CrossRefGoogle ScholarPubMed
4.Sanchez, C, Asin, KE, Artigas, F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther. 2015; 145: 43–57.CrossRefGoogle ScholarPubMed
5.Stahl, SM. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): enhancing serotonin release by combining serotonin (5HT)transporter inhibition with action at 5HT receptors (5HT1A, 5HT1B, 5HT1D, 5HT7 receptors). CNS Spectr. 2015; 20(2): 93–97.CrossRefGoogle ScholarPubMed
6.Stahl, SM. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): modifying serotonin’s downstream effects on glutamate and GABA (gamma-amino-butyric acid) release by blocking 5HT3 and 5HT7 receptors. CNS Spectr In press.Google Scholar
7.Stahl, SM. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): actions at serotonin receptors may enhance downstream release of four pro-cognitive neurotransmitters. CNS Spectr In press.Google Scholar
8.Mørk, A, Montezinho, LP, Miller, S. Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. Pharmacol Biochem Behav. 2013; 105: 41–50.CrossRefGoogle ScholarPubMed
9.Stahl, SM. Stahl’s Essential Psychopharmacology. 4th ed. Cambridge, UK: Cambridge University Press; 2013.Google Scholar
10.Fink, KB, Gothert, M. 5HT receptor regulation of neurotransmitter release. Pharmacol Rev. 2007; 59(4): 360–417.CrossRefGoogle ScholarPubMed
11.Gehlert, DR, Gackenheimer, SL, Wong, DT, Robertson, DW. Localization of 5-HT3 receptors in the rat brain using [3H]LY278584. Brain Res. 1991; 553(1): 149–154.CrossRefGoogle ScholarPubMed
12.Puig, MV, Santana, N, Celada, P, Mengod, G, Artigas, F. In vivo excitation of GABA interneurons in the medial prefrontal cortex through 5-HT3 receptors. Cereb Cortex. 2004; 14(12): 1365–1375.CrossRefGoogle Scholar
13.Morales, M, Battenberg, E, Bloom, FE. Distribution of neurons expressing immunoreactivity for the 5HT3 receptor subtype in the rat brain and spinal cord. J Comp Neurol. 1998; 402(3): 385–401.3.0.CO;2-Q>CrossRefGoogle ScholarPubMed
14.Morales, M, Bloom, FE. The 5-HT3 receptor is present in different subpopulations of GABAergic neurons in the rat telencephalon. J Neurosci. 1997; 17(9): 3157–3167.CrossRefGoogle ScholarPubMed
15.Ashby, CR Jr, Minabe, Y, Edwards, E, Wang, RY. 5-HT3-like receptors in the rat medial prefrontal cortex: an electrophysiological study. Brain Res. 1991; 550(2): 181–191.CrossRefGoogle ScholarPubMed
16.Dale, E, Zhang, H, Leiser, S, et al. Vortioxetine disinhibits pyramidal cell function and enhances synaptic plasticity in rat hippocampus. J Psychopharmacol. 2014; 28(10): 891–902.CrossRefGoogle ScholarPubMed
17.Bétry, C, Pehrson, AL, Etievant, A, et al. The rapid recovery of 5HT cell firing induced by the antidepressant vortioxetine involves 5HT3 receptor antagonism. Int J Neuropsychopharmacol. 2013; 16(5): 1115–1127.CrossRefGoogle ScholarPubMed
18.Artigas, F. Serotonin receptors involved in antidepressant effects. Pharmacol Ther. 2013; 137(1): 119–131.CrossRefGoogle ScholarPubMed
19.Matsumoto, M, Yoshioka, M, Togashi, H, Tochihara, M, Ikeda, T, Saito, H. Modulation of norepinephrine release by serotonergic receptors in the rat hippocampus as measured by in vivo microdialysis. J Pharmacol Exp Ther. 1995; 272(3): 1044–1051.Google ScholarPubMed
20.Yan, Z. Regulation of GABAergic inhibition by serotonin signaling in prefrontal cortex: molecular mechanisms and functional implications. Mol Neurobiol. 2002; 26(2–3): 203–216.CrossRefGoogle ScholarPubMed
21.Siarey, RJ, Andreasen, M, Lambert, JDC. Serotoninergic modulation of excitability in area CA1 of the in vitro rat hippocampus. Neurosci Lett. 1995; 199(3): 211–214.CrossRefGoogle ScholarPubMed
22.Zhou, F, Hablitz, JJ. Activation of serotonin receptors modulates synaptic transmission in rat cerebral cortex. J Neurophysiol. 1999; 82(6): 2989–2999.CrossRefGoogle ScholarPubMed
23.Giovannini, MG, Ceccarelli, I, Molinari, B, Cecci, M, Goldfarb, J, Blandina, P. Serotonergic modulation of acetylcholine release from cortex of freely moving rats. J Pharmacol Exp Ther. 1998; 285(3): 1219–1225.Google ScholarPubMed
24.Pehrson, AL, Sanchez, C. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr. 2014; 19(2): 121–133.CrossRefGoogle ScholarPubMed
25.Puig, MV, Gulledge, AT. Serotonin and prefrontal cortex function: neurons, networks, and circuits. Mol Neurobiol. 2011; 44(3): 449–464.CrossRefGoogle ScholarPubMed
26.Kubota, Y. Untangling GABAergic wiring in the cortical microcircuit. Curr Opin Neurobiol. 2014; 26: 7–14.CrossRefGoogle ScholarPubMed
27.Adesnik, H, Scanziani, M. Lateral competition for cortical space by layer-specific horizontal circuits. Nature. 2010; 464(7292): 1155–1160.CrossRefGoogle ScholarPubMed
28.Gottlieb, JP, Keller, A. Intrinsic circuitry and physiological properties of pyramidal neurons in rat barrel cortex. Exp Brain Res. 1997; 115(1): 47–60.CrossRefGoogle ScholarPubMed
29.Izumi, J, Washizuka, M, Miura, N, Hiraga, Y, Ikeda, Y. Hippocampal serotonin 5HT1A receptor enhances acetylcholine release in conscious rats. J Neurochem. 1994; 62(5): 1804–1808.CrossRefGoogle ScholarPubMed
30.Consolo, S, Ramponi, S, Ladinsky, H, Baldi, G. A critical role for D1 receptors in the 5HT1A-mediated facilitation of in vivo acetylcholine release in rat frontal cortex. Brain Res. 1996; 707: 320–323.CrossRefGoogle Scholar
31.Suzuki, M, Matsuda, T, Asano, S, Somboonthum, P, Takuma, K, Baba, A. Increase of noradrenaline release in the hypothalamus of freely moving rat by postsynaptic 5-hydroxytryptamine 1A receptor activation. Br J Pharmacol. 1995; 115(4): 703–711.CrossRefGoogle Scholar
32.Suwabe, A, Kubota, M, Niwa, M, Kobayashi, K, Kanba, S. Effect of a 5HT1A receptor agonist, flesinoxan, on the extracellular noradrenaline level in the hippocampus and on the locomotor activity of rats. Brain Res. 2000; 858(2): 393–401.CrossRefGoogle ScholarPubMed
33.Brambilla, A, Ghiorzi, A, Pitsikas, N, Borsini, F. DAU 6215, a novel 5HT3 receptor antagonist selectively antagonizes scopolamine-induced deficit in a passive avoidance task, but not scopolamine induced hypermotility in rats. J Pharm Pharmacol. 1993; 45(9): 841–843.CrossRefGoogle Scholar
34.Fontana, DJ, Daniels, SE, Henderson, C, Eglen, RM, Wong, EH. Ondansetron improves cognitive performance in the Morris water maze spatial navigation task. Psychopharmacol (Berl). 1995; 120(4): 409–417.CrossRefGoogle ScholarPubMed
35.Pitsikas, N, Borsini, F. Itasetron (DAU 6215) prevents age-related memory deficits in the rat in a multiple choice avoidance task. Eur J Pharmacol. 1996; 311(2–3): 115–119.CrossRefGoogle Scholar
36.Roychoudhury, M, Kulkarni, SK. Effects of ondansetron on short-term memory retrieval in mice. Methods Find Exp Clin Pharmacol. 1997; 19(1): 43–46.Google ScholarPubMed
37.Arnsten, AF, Line, CH, Van Dyck, CH, Stanhope, KJ. The effects of 5HT3 receptor antagonists on cognitive performance in aged monkeys. Neurobiol Aging. 1997; 18(1): 21–28.CrossRefGoogle ScholarPubMed
38.du Jardin, KG, Jensen, JB, Sanchez, C, Pehrson, AL. Vortioxetine dose dependently reverses 5HT depletion induced deficits in spatial working and object recognition memory: a potential role of 5HT1A receptor agonism and 5HT3 receptor antagonism. Eur Neuropsychopharmacol. 2014; 24(1): 160–171.CrossRefGoogle ScholarPubMed
39.Jensen, JB, du Jardin, KG, Song, D, et al. Vortioxetine, but not escitalopram or duloxetine, reverses memory impairment induced by central 5HT depletion in rats: evidence for direct 5HT receptor modulation. Eur Neuropyschopharmacol. 2014; 24(1): 148–159.CrossRefGoogle ScholarPubMed
40.Li, Y, Sanchez, C, Gulinello, M. Memory impairment in old mice is differentially sensitive to different classes of antidepressants. Eur Neuropsychopharmacol. 2013; 23(Suppl 2): S282.CrossRefGoogle Scholar
41.Wallace, A, Pehrson, AL, Sánchez, C, Morilak, DA. Vortioxetine restores learning impaired by 5HT depletion or chronic intermittent cold stress in rats. Int J Neuropsychopharmacol. 2014; 17(10): 1695–1706.CrossRefGoogle ScholarPubMed
42.Katona, C, Hansen, T, Olsen, CK. A randomized, double blind, placebo controlled, duloxetine referenced, fixed dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012; 27(4): 215–223.CrossRefGoogle ScholarPubMed
43.McIntyre, RS, Lophaven, S, Olsen, C. A randomized, double-blind, placebo controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol. 2014; 17(10): 1557–1567.CrossRefGoogle ScholarPubMed
44.Mahableshwarkar, AR, Zajecka, J, Jacobson, W, Chen, Y, Keefe, RSE. A randomized, placebo-controlled, active-reference, double blind, flexible dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology In press. DOI: 10.1038/npp.2015.52.Google Scholar
45.Insel, T, Cuthbert, B, Garvey, M, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010; 167(7): 748–751.CrossRefGoogle Scholar
46.Stahl, SM. The last diagnostic and statistical manual (DSM): replacing our symptom-based diagnoses with a brain circuit-based classification of mental illnesses. CNS Spectr. 2013; 18(2): 65–68.CrossRefGoogle ScholarPubMed
Figure 0

Figure 1 Icon of vortioxetine showings its 6 pharmacologic mechanisms. Highlighted here is 5HT3 antagonism, linked to enhanced release of serotonin (5HT), NE, and ACh.

Figure 1

Figure 2A Serotonin and glutamate regulate each other: role of 5HT3 receptors. Shown here is a 3-neuron feedback circuit, beginning with the 5HT neuron, terminating upon a 5HT3 receptor localized upon a second neuron: a GABAergic interneuron that does not stain positively for the calcium binding protein parvalbumin and has a firing pattern that is regular spiking, late spiking or bursting. GABA released from this second neuron in turn inhibits the third neuron in this feedback circuit: cortical pyramidal neurons that release glutamate at nerve terminals that project back to the midbrain raphe and that stimulate 5HT release.

Figure 2

Figure 2B When 5HT levels increase after administration of an SSRI, the activation of 5HT3 receptors by 5HT leads to stimulation of GABA release; this in turn inhibits cortical pyramidal neurons, and thus there is no amplification of 5HT release by downstream glutamate.

Figure 3

Figure 2C In contrast to the actions of SSRIs shown in Figure 2B, shown here are the actions of vortioxetine, which not only enhance 5HT via SERT inhibition, but also block 5HT3 receptors. The blockade of 5HT3 receptors removes GABA inhibition and thus disinhibits pyramidal neurons. This in turn enhances downstream release of 5HT due to glutamatergic stimulation of serotonergic neurons in the midbrain raphe.

Figure 4

Figure 3A Serotonin (5HT) 3 receptor mediated regulation of ACh and NE release. 5HT stimulation of 5HT3 receptors causes inhibitory output from GABAergic interneurons, and this inhibits the release of NE and ACh from presynaptic nerve terminals.

Figure 5

Figure 3B SSRIs inhibit the release of ACh and NE via 5HT3 receptors. When SSRIs increase 5HT levels by SERT inhibition, GABA is released, which in turn inhibits both NE and ACh release.

Figure 6

Figure 3C Vortioxetine enhances the release of ACh and NE by blocking 5HT3 receptors. By contrast with SSRI actions shown in Figure 3B, vortioxetine blocks the 5HT3 receptor so that GABA is not released by 5HT, and therefore both NE and ACh are disinhibited—ie, their levels are enhanced.